Idioma:

The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial

Parfrey, Patrick S ; Chertow, Glenn M ; Block, Geoffrey A ; Correa-Rotter, Ricardo ; Drüeke, Tilman B ; Floege, Jürgen ; Herzog, Charles A ; London, Gerard M ; Mahaffey, Kenneth W ; Moe, Sharon M ; Wheeler, David C ; Dehmel, Bastian ; Trotman, Marie-Louise ; Modafferi, Dennis M ; Goodman, William G

The journal of clinical endocrinology and metabolism, 2013-12, Vol.98 (12), p.4834-4844 [Periódico revisado por pares]

Bethesda, MD: Endocrine Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial
Autor: Parfrey, Patrick S ; Chertow, Glenn M ; Block, Geoffrey A ; Correa-Rotter, Ricardo ; Drüeke, Tilman B ; Floege, Jürgen ; Herzog, Charles A ; London, Gerard M ; Mahaffey, Kenneth W ; Moe, Sharon M ; Wheeler, David C ; Dehmel, Bastian ; Trotman, Marie-Louise ; Modafferi, Dennis M ; Goodman, William G
Assuntos: Adult ; Aged ; Biological and medical sciences ; Bone Diseases, Metabolic - physiopathology ; Bone Diseases, Metabolic - therapy ; Calcimimetic Agents - administration & dosage ; Calcimimetic Agents - therapeutic use ; Cinacalcet Hydrochloride ; Combined Modality Therapy - adverse effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; Endocrinopathies ; Feeding. Feeding behavior ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Humans ; Hypercalcemia - etiology ; Hypercalcemia - prevention & control ; Hyperparathyroidism, Secondary - drug therapy ; Hyperparathyroidism, Secondary - etiology ; Hyperparathyroidism, Secondary - physiopathology ; Hyperparathyroidism, Secondary - surgery ; Kidney Failure, Chronic - physiopathology ; Kidney Failure, Chronic - therapy ; Male ; Medical sciences ; Middle Aged ; Naphthalenes - administration & dosage ; Naphthalenes - therapeutic use ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Parathyroidectomy - adverse effects ; Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) ; Proportional Hazards Models ; Renal Dialysis - adverse effects ; Severity of Illness Index ; Vertebrates: anatomy and physiology, studies on body, several organs or systems ; Vertebrates: endocrinology
É parte de: The journal of clinical endocrinology and metabolism, 2013-12, Vol.98 (12), p.4834-4844
Notas: This study was funded by Amgen, Inc and led by an executive committee composed of academic members, two sponsor members (nonvoting), and statisticians. The executive committee oversaw the design, conduct, and all analyses. Data were collected by the sponsor and shared with the executive committee throughout the study and after unblinding. The analysis was performed by the sponsor and confirmed by an independent biostatistician at Stanford University School of Medicine. The sponsor provided the active medication and matching placebo. The lead author wrote the first draft of the manuscript, and the executive committee was responsible for data interpretation and manuscript completion. The sponsor reviewed the manuscript, but decisions about the final manuscript were made by the lead author and academic members of the executive committee only. All authors vouch for the integrity of the data.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
Descrição: Context: The clinical course of secondary hyperparathyroidism (sHPT) in patients on hemodialysis is not well described, and the effect of the calcimimetic cinacalcet on disease progression is uncertain. Objective: Our objective was to describe 1) the clinical course of sHPT in patients treated with phosphate binders and/or vitamin D sterols and 2) the impact of cinacalcet on the occurrence of severe unremitting HPT, defined by the persistence of markedly elevated PTH concentrations together with hypercalcemia or parathyroidectomy (PTX). Design and Setting: This was a randomized, double-blind, placebo-controlled, global, multicenter clinical trial. Patients: Of 5755 patients screened with moderate to severe sHPT, 3883 patients on hemodialysis were included in the trial. Main Outcome Measures: Outcomes included PTX; severe, unremitting HPT; and use of commercial cinacalcet (a protocol violation). Intervention: Intervention was cinacalcet (30–180 mg daily) or placebo for up to 64 months. Results: In the 1935 patients randomized to placebo, 278 patients (14%) underwent PTX (median PTH 1872 pg/mL within the previous 12 weeks from surgery). Age, sex, geographic region, co-morbidity, calcium-containing phosphate binder use, and baseline serum calcium, phosphorus, and PTH concentrations were associated with PTX. Commercial cinacalcet was started in 443 (23%) patients (median PTH 1108 pg/mL before treatment began). Severe unremitting HPT developed in 470 patients (24%). In a multivariable Cox model, the relative hazard (comparing patients randomized to cinacalcet versus placebo) of severe unremitting HPT was 0.31 (95% confidence interval = 0.26–0.37). The relative hazard differed little when adjusted by baseline clinical characteristics. Conclusions: Severe unremitting HPT develops frequently in patients on hemodialysis despite conventional therapy, and cinacalcet substantially reduces its occurrence.
Editor: Bethesda, MD: Endocrine Society
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial

Bethesda, MD: Endocrine Society

Buscando em bases de dados remotas. Favor aguardar.